Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

NCT01684761 is registered in ClinicalTrials.gov with Opexa Therapeutics, Inc. as lead sponsor.

NCT NCT01684761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01684761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Lead sponsor
Opexa Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
October 31, 2016
Enrollment
183 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases of the nervous system, brain atrophy, disease progression, multiple sclerosis, secondary progressive multiple sclerosis